Impel Pharmaceuticals Inc.
Intranasal delivery of olanzapine by precision olfactory device

Abstract:

Methods are provided for acute treatment of agitation, including agitation in patients with schizophrenia or bipolar disorder, comprising administering to a subject with agitation an effective dose of a dry pharmaceutical composition comprising olanzapine, wherein the dose is administered by an intranasal delivery device that provides, following intranasal administration, (a) a mean peak plasma olanzapine concentration (C.sub.max) of at least 30 ng/mL, with (b) a mean time to C.sub.max (T.sub.max) of olanzapine of less than 0.5 hours. Dry pharmaceutical compositions and devices suitable for intranasal delivery of olanzapine are provided.